Search clinical trials for: Icotinib Hydrochloride

Total 9539 results

Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche

Unknown

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Systemic Sclerosis

Italy
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Cream For Atopic Dermatitis

Atopic Dermatitis

China
SK Chemicals Co., Ltd.
Toray Industries, Inc

Completed

Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis (TRK-820)

Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis

Korea, Republic of
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
Medical College of Wisconsin
H. Jean Khoury Cure CML Consortium

Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia

United States
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China
Orexigen Therapeutics, Inc

Terminated

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Obesity | Overweight

United States
Oslo University Hospital
University Hospital of North Norway; Helse Stavanger HF; Haukeland University... and other collaborators

Not yet recruiting

Precision Cancer Therapy in Rare Cancers (MATRIX-Rare)

Rare Malignant Neoplasm
PETHEMA Foundation

Recruiting

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Acute Lymphoblastic Leukemia Ph Positive

Spain
Yonsei University

Completed

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Fibromatosis

Korea, Republic of
St. Justine's Hospital

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Plexiform Neurofibromas

Canada
Cttq
Ruijin Hospital

Unknown

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Novartis

Completed

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis

Completed

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Seasonal Allergic Rhinitis

United Kingdom
M.D. Anderson Cancer Center
Novartis

Completed

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Agnogenic Myeloid Metaplasia

United States
BioCryst Pharmaceuticals

Terminated

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

Lymphoma | Leukemia

United States
Samsung Medical Center

Active, not recruiting

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Advanced, Refractory Cancer

Korea, Republic of
Georgetown University

Unknown

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib in Chordoma

Chordoma

Switzerland, Italy
Novartis Pharmaceuticals

Completed

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors

Italy
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Carcinoma, Adenoid Cystic | Cancer of the Head and Neck

France
Hospices Civils de Lyon

Unknown

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

Acute Lymphocytic Leukemia

France
Novartis Pharmaceuticals

No longer available

Nilotinib, for Patients With CML-CP or CML-AP

Chronic Myelogenous Leukemia (CML)
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib in PH+, BCR-, ABL+ CML Patients (CML0811)

Chronic Myeloid Leukemia

Italy
Novartis Pharmaceuticals

Completed

Tasigna in Glivec-resistant or Intolerant Patients in CML

CML | Nilotinib | Imatinib Resistant | Imatinib Intolerant

Korea, Republic of
Novartis Pharmaceuticals

Approved for marketing

Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Mexico
Eisai Co., Ltd.

Completed

A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)

Dementia With Lewy Bodies (DLB)

Japan
Azienda Ospedaliera Universitaria Integrata Verona
University of Milan

Unknown

Prasugrel in Severe COVID-19 Pneumonia (PARTISAN)

Thrombosis | COVID19

Italy
National Taiwan University Hospital
National Cheng-Kung University Hospital; Far Eastern Memorial Hospital; Tri-Service... and other collaborators

Terminated

Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Patients Who Have Received Allo-HSCT

Taiwan
European Organisation for Research and Treatment...
UNICANCER; Grupo Espanol de Investigacion en Sarcomas; Italian Sarcoma Group

Completed

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

France, Australia, United Kingdom, Germany, Denmark, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Brain and Central Nervous System Tumors

United States
Professor Mikael Svensson, MD PhD

Unknown

Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study

Cervical Spinal Cord Injury
Shanghai Zhongshan Hospital
Changhai Hospital; Fudan University; Huashan Hospital; Ruijin Hospital; Shanghai...

Unknown

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST

China
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
Novartis Pharmaceuticals

Completed

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (CONVERT)

Gastrointestinal Stromal Tumors

Brazil
Novartis Pharmaceuticals

Completed

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

Healthy
Università degli Studi di Brescia

Completed

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy (INTERIM0407)

Chronic Myeloid Leukemia

Italy
University of California, Los Angeles
Novartis Pharmaceuticals

Completed

A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis

Systemic Sclerosis | Alveolitis

United States
Indiana University School of Medicine

Completed

Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma

Thymic Carcinoma

United States
Novartis

Completed

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Leukemia

United States
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Chronic Myeloid Leukemia

France
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States
Peking University
Novartis

Completed

Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma

Metastatic Melanoma

China

Search clinical trials for: Icotinib Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations